EDGAR·FLOW

Amylyx Pharmaceuticals, Inc. — Form 10-Q

Filed November 5, 2026 · analyzed by the Periodic Agent
10-Q ▲ Likely positive significance 72/100
What the filing says
Amylyx signed two manufacturing and supply agreements: (1) Bachem Americas for an unspecified active pharmaceutical ingredient with a June 2025 LOI providing guaranteed manufacturing slots and capacity commitment (details redacted); (2) PolyPeptide Group AG for Avexitide with an 8-year initial term, minimum annual quantities (redacted), tiered pricing from USD [***] per unit, and non-refundable pre-payments of USD 30 million capacity reservation plus Post-PPQ pre-payment (redacted). Both agreements govern long-term commercial supply with detailed quality, delivery, and termination provisions.
Why this rating

Dual CDMO partnerships are material for a $518M biotech; secure supply reduces regulatory risk. Pre-payments of $30M+ represent ~6% of market cap, substantial but typical for pharma manufacturing. Avexitide supply lock-in supports commercialization if approved, but approval status and pricing remain redacted.

Tradability signal
NO TRADE

No trade: the filing reads positive but the market is selling it (-4.4% since it hit EDGAR) — when our read and the tape disagree this hard, we stand aside. (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
at our read · unknown
$29.85
+10 min · unknown
$29.68 ▼ 0.55%
+30 min · unknown
$29.34 ▼ 1.73%
+1 hr · unknown
$29.52 ▼ 1.11%
+4 hrs · unknown
$28.39 ▼ 4.91%

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ AMLX · stock on Yahoo Finance ↗

See more from November 5, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.